Kornimate/medical-research-clean huggingface dataset:
decision support tools for men with prostate cancer- clinical & lifestyle model

Conditions: Prostate Cancer

Summary: a ucsf pi-initiated study with a primary goal to improve decision quality, anxiety, and uncertainty, thereby increasing appropriate uptake of active surveillance and reducing over-treatment of low-risk prostate cancer. this study involves: completion of questionnaires through the secure website; consultation by a health coach to aid men with prostate cancer in making informed treatment decision (personalized coaching session(s)).

a ucsf pi-initiated study which includes comprehensive decision support intervention that may incorporate clinical, lifestyle, tumor genomic, and germline gene variant data. the web and coaching intervention will: 1) summarize key prognostic data elements, 2) communicate relative and absolute risks of upgrading/upstaging based on each of these elements, individually and in aggregate, and 3) provide tailored educational information for informed decision making on treatment options. a key aspect of the intervention will be provision of tiered coaching to the men prior to their physician visits to help them enter information accurately into the system, understand the results of the prediction model, document their questions for their physicians, and prepare them to make better-informed treatment decisions. ucsf research team will develop the decision support intervention in phases, initially using only clinical variables, bmi (body mass index), and smoking data;and then extend it to include information from genomic and genetic inputs, as validation work progresses. variables will be retained based on statistical evaluation of the predictive values.

Eligibility criteria:
inclusion criteria are the following: 1. men \>18 years of age with newly diagnosed (within 3 month) low risk prostatecancer , who have not yet received cancer-directed therapy, or men who are at risk of prostate cancer and coming to have a diagnostic biopsy, and diagnosed with low grade of prostate cancer 2. biopsy gleason score \< 3+3, 3. has localized (clinical stage \< t2n0m0) prostate cancer with a psa \<10ng/ml 4. consent to research follow-up exclusion criteria: 1. men with missing data on psa, stage, gleason, or extent of biopsy core involvement; no baseline (diagnostic) biopsy or germline dna sample for research; or no follow-up pathology (from biopsy or rp) after diagnosis. 2. men unable to consent, prisoners, those with ecog performance status \>2, or psychiatric illness/social situations that would limit compliance with study requirements, or inability to read english or spanish.

Keywords: prostate cancer tranformative impact award early stage active surveillance decision aid coaching session personalized ucsf validation
aberrant expression of cd56 in patients with hematologic malignancies.

Conditions: Hematologic Malignancies

Summary: cd56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . a met analysis indicated that cd56 over expression may be an adverse prognostic factor in aml. to the best of our knowledge, no available data the expression pattern of cd56 in other hematologic malignancies. this work is designed to evaluate the expression pattern of cd56 in hematologic malignancies.

cd56 is the archetypal phenotypic marker of natural killer cells but can actually be expressed by many more immune cells, including alpha, beta t cells, gamma, delta t cells, dendritic cells, and monocytes. common to all these cd56 expressing cell types have strong immunostimulatory effector functions, including t helper 1 cytokine production and an efficient cytotoxic capacity. interestingly, both numerical , functional deficiencies and phenotypic alterations of the cd56 immune cell fraction have been reported in patients with various infectious, autoimmune, or malignant diseases.cd56 is also known as neural cell adhesion molecule (ncam). hematologic malignancies are a heterogeneous group of diseases of diverse incidence, prognosis and etiology that arise from malignant transformation of cells from the bone marrow or the lymphatic system.there are two major groups of hematologic malignancies according to their cell lineage: myeloid and lymphoid. lymphoid neoplasms are a varied group that includes non-hodgkin lymphoma (nhl), hodgkin lymphoma (hl), leukemia and multiple myeloma (mm).myeloid neoplasms and acute leukaemia include: myeloproliferative neoplasms (mpn), myelodysplastic/myeloproliferative neoplasms (mds/mpn), myelodysplastic syndromes (mds), acute myeloid leukaemia (aml), acute leukemias of ambiguous lineage, b-lymphoblastic leukaemia/lymphoma, t-lymphoblastic leukaemia/lymphoma.the exact causes of hematologic malignancies are still unknown although multiple epidemiological studies have reported an association between the development of hematologic malignancies and several risk factors. some factors are well documented to increase the risk of some types of leukaemia such as benzene exposure and ionizing radiation.however, many other factors were observed to have an association with hematologic malignancies such as age, gender, tobacco smoking , obesity , hepatitis c virus (hcv) infection , family history , and environmental exposure to pesticides but with no clear evidence. cd56 was found to be ectopically expressed in multiple myeloma. a met analysis indicated that cd56 over expression may be an adverse prognostic factor in aml. to the best of our knowledge, no available data the expression pattern of cd56 in other hematologic malignancies. this work is designed to evaluate the expression pattern of cd56 in hematologic malignancies.

Eligibility criteria:
inclusion criteria: * patients with hematologic malignancies. * newly diagnosed exclusion criteria: * patients with hematologic disorders other than hematologic malignancies.
evaluation of the clinical performance of the quantra system with the qstat cartridge

Conditions: Blood Loss Massive; Trauma; Hemorrhage, Postpartum

Summary: this pilot study will evaluate the performance of the quantra system comprised of the quantra hemostasis analyzer with the qstat cartridge in trauma patients or patients with ob hemorrhage.

the quantra system is a fully integrated and automated in vitro diagnostic device which uses seer sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. the qstat cartridge was developed to monitor hemostasis in patients that may experience a range of coagulopathies of various etiologies including fibrinolytic defects. these patients include the trauma and obstetric hemorrhage populations. the cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed in parallel yielding five parameters that depict the functional status of a patient's coagulation system. this single-center, prospective, observational pilot study will evaluate the performance of the quantra system with the qstat cartridge as compared to standard coagulation tests and comparable measures using conventional viscoelastic testing methods.

Eligibility criteria:
inclusion criteria: * subject is ≥ 18 years of age * subject has one of the following conditions and is a candidate for a rotem test to be performed to access coagulopathy: trauma patient; patient with ob hemorrhage. * for trauma patients; subject must be experiencing major trauma (preferably requiring the highest level of team activation) with active bleeding or deemed at high risk of significant bleeding according to mechanism of injury. * for subjects experiencing ob hemorrhage, one of the following conditions must be met (to be confirmed): * estimated blood loss during vaginal delivery is greater than 1000 ml * estimated blood loss during cesarean delivery is greater than 1500 ml * placental abruption with hemorrhage of any quantity blood loss * clinically suspected disseminated intravascular coagulation (dic) * is under consideration for administration of tranexamic acid (txa) for treatment of hemorrhage. * subject is willing to participate, and is willing to consent (either prospectively or by deferred consent) exclusion criteria: * subject is younger than 18 years of age * subject is known to have received antifibrinolytic therapy immediately prior to presentation to trauma unit or during labor just prior to ob hemorrhage. * subject is unable to provide written informed consent (either prior to performing any study related procedures or by deferred consent) * subject is currently enrolled in a distinct study that might confound the results of the proposed study * subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks.

Keywords: viscoelastic testing coagulation quantra hemostasis
personalized care pathways for bowel symptoms in rectal cancer patients_contributing factors (treatable)

Conditions: Rectal Cancer; LARS - Low Anterior Resection Syndrome

Summary: colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. the gold standard treatment for rectal cancer (rc) is a low anterior resection, combined with chemoradiotherapy. however, this treatment will negatively impact different aspects of bowel function and the patients' quality of life. these bowel symptoms often remain prevalent, even at 12 months after rc treatment. the aim of this study is to identify the factors contributing to persistent bowel symptoms and their long-term impact on quality of life following treatment for rectal cancer 12 month post-surgery or post-stoma closure. these insights are crucial in developing an effective care approach, as they assist us in determining when specific evaluations should be conducted and which treatments should be applied at different stages.


Eligibility criteria:
inclusion criteria: * voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures. * at least 18 years of age at the time of signing the informed consent form (icf). * proficient in reading, comprehending, and conversing in dutch. * patients scheduled for total mesorectal excision (tme) or partial mesorectal excision (pme) or 'watch and wait' protocol due to rectal cancer. exclusion criteria: * the participant has undergone a different type of surgery, including a hartmann procedure, abdominoperineal excision, transanal endoscopic microsurgery, or sigmoid resection. * experienced fecal incontinence prior to undergoing surgery. * are affected by neurological disorders affecting bowel function. * already underwent previous pelvic surgery, previous pelvic radiation or rectal surgery for non-cancer reasons. * has a permanent stoma.

Keywords: bowel diary quality of life (qol) care pathway
a study of a renal autologous cell therapy (react) in patients with chronic kidney disease (ckd) from congenital anomalies of the kidney and urinary tract (cakut).

Conditions: Chronic Kidney Disease; Congenital Anomalies of Kidney and Urinary Tract

Summary: a phase 1, open-label safety, tolerability and early efficacy study of a renal autologous cell therapy (react) in patients with chronic kidney disease from congenital anomalies of the kidney and urinary tract (cakut) (regen-004)

it is anticipated that all subjects will receive two planned renal autologous cell therapy (react) injections to allow dose-finding and evaluate the duration of effects. the scientific rationale, based on non-clinical studies, is that the biologically active component of react (homologous, autologous, src) delays progression of experimental models of chronic kidney disease (ckd) by augmenting renal structure and function. as a result, the more cells that can be infused, the greater the potential improvement in renal function.

Eligibility criteria:
inclusion criteria: 1. the patient is male or female, 18 to 65 years of age on the date of informed consent. 2. the patient has a documented history of a corrected abnormality of the kidney and/or urinary tract (cakut) leading to renal dysfunction. 3. the patient has an established diagnosis of stage iii/iv ckd not requiring renal dialysis. 4. the subject has blood pressure less than 150/90 at the screening visit, prior to renal biopsy, and prior to react injection(s). exclusion criteria: 1. the patient has a history of renal transplantation. 2. the patient has a diagnosis of hydronephrosis, sfu grade 4 or 5. 3. the patient has an uncorrected vur grade 5. 4. the patient has a diffuse cortical thickness throughout the kidney measuring \< 5 mm on mri that prevents safe cortical biopsy.
cough determinants in mechanically ventilated patients

Conditions: Mechanical Ventilation

Summary: in our knowledge there is only few data about the cough determinants in mechanically ventilated patients. however some failure of extubation is due to inefficiency cough. in order to determine some determinants of cough, the investigators propose to evaluate systematically different physiological parameters before and after extubation.

in order to evaluate, and identify the cough determinants, the investigators propose a physiological evaluation for each patients who were intubated and mechanically ventilated during at least 72 hours. indeed inefficacy of cough after extubation is one of the main reason of extubation failure. however there is no any mean to evaluate it simply now.

Eligibility criteria:
inclusion criteria: * patients mechanically ventilated since 72h * age \> 18 years * hospitalized in intensive care unit * in weaning phase - with the classically criteria to be extubated * patients who passed the weaning test (t tube test or other) exclusion criteria: * hemodynamic instability * absence of consent * no cooperation of the patient * hemodynamic instability * ph \< 7,30 * severe hypoxemia
transcranial doppler using wearable ultrasound patch

Conditions: Medical Device Complication; Brain Injuries; Brain Diseases; Stroke; Vasospasm

Summary: the main objective of this research is to measure the doppler signal by the ultrasonic patch. blood flow measurement is critical for vasospasm, stroke, and embolism monitoring on patients in the icu or understanding the neurovascular coupling on different subjects. currently, a conventional transcranial doppler (tcd) probe is widely used for these applications. a headset design must be applied and fixed on the participants to obtain stable blood flow spectra. however, the tcd headset is operator dependent. the operator needs to be a trained expert and hold the ultrasound probe to get accurate blood flow velocity information. the stretchable and wearable non-invasive ultrasonic patch can not only free the operator's hands but can also provide long-term continuous monitoring, which is not possible by using the current operator-dependent ultrasound machine. the device can be conformal to the skin and attached to the skin surface.


Eligibility criteria:
inclusion criteria: * able to provide informed consent. * in relatively good health with no serious medical conditions. exclusion criteria: * inability to sign the informed consent. * history of the following conditions: heart attack, low blood pressure, aortic stenosis/carotid artery stenosis (also known as heart valve disease), glaucoma (a group of eye conditions that damage the optic nerve) or retinopathy (a disease of the eye retina).
comparison of preoperative frailty assessment tools

Conditions: Frailty; Frailty in Older Adults; Frailty/Sarcopenia

Summary: frailty is a significant risk factor for postoperative complications and functional decline. preoperative assessment of frailty is therefore recommended in all older adults. however, despite the availability of many frailty tools, few have been tested in the preoperative setting and there is little comparison of their predictive value in identifying patients at risk. the aim of this study is to investigate which of the following instruments for determining frailty has the highest predictive power with regard to the occurrence of postoperative complications: risk analysis index, clinical frailty scale, the groningen frailty indicator, the edmonton frail scale and the lucas-fi. the aim of this research project is to identify a suitable frailty instrument for preoperative risk stratification of older patients during the premedication visit.


Eligibility criteria:
inclusion criteria: * 70 years and older * scheduled surgery * estimated time of surgery 120 minutes or more exclusion criteria: * insufficient german language skills (for cognitive testing) * mental retardation * relevant psychiatric disorder (not allowing for cognitive testing)
effects of metformin, pegylated interferon alpha and ribavirin for chronic hepatitis c with insulin resistance

Conditions: Chronic Hepatitis c; Insulin Resistance

Summary: the aim of the study is to investigate the treatment response of metformin, peg-ifn and ribavirin combination therapy for chronic hepatitis c virus (hcv).

current standard of treatment for hcv with pegylated interferon(peg-ifn)-alpha and ribavirin can achieve sustained virological response (svr) in only 60-90% of patients. insulin resistance is an important factor of non-response to combination therapy. metformin is a insulin sensitizer and can effectively reduce insulin resistance. the aim of the study is to investigate the treatment response of metformin, peg-ifn and ribavirin combination therapy for chronic hcv.

Eligibility criteria:
inclusion criteria: * hcv rna (+) and alt \> 40 u/l * compensated liver * homa-ir \> 2 exclusion criteria: * neutrophil \<1500/mm3 * male: hb \< 13 g/dl, female: hb \< 12 g/dl * platelet \< 80,000 /mm3 * cr \> 2.5 mg/dl * alcohol use \> 20 gm per day * uncontrolled depression, thyroid disease, autoimmune disease * pregnancy * hepatocellular carcinoma * allergy to interferon or ribavirin * diabetes * hbv/hiv co-infection

Keywords: hepatitis c metformin pegylated interferon
non-vitamin k oral anticoagulants in cardioversion

Conditions: Atrial Fibrillation

Summary: non-vitamin k oral anticoagulants (noac) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular af (nvaf). there are yet limited real life data on outcomes following elective cardioversion in af patients treated with noacs. the aim of this study is to investigate the complications and the use of noacs in af patients undergoing cardioversion.


Eligibility criteria:
inclusion criteria: * af patients undergoing cardioversion exclusion criteria: -

Keywords: atrial fibrillation anticoagulation cardioversion
the jintronix interactive system for upper extremity rehabilitation training post stroke

Conditions: Stroke

Summary: stroke is a leading cause of death and disability worldwide.hemiplegia, weakness of one side of the body, is a common consequence of stroke that can lead to significant functional impairments. loss of arm function occurs in up to 85% of stroke survivors. the impact of arm-related limitations on activities of daily living, leisure activities or work is significant as the arm plays a central role in a person's life from the ability to perform basic activities of daily life to carrying out family and social roles. guidelines indicate that rehabilitation can improve upper extremity (ue) motor control and functional status post stroke. virtual reality (vr) and computer games are recent technologies that, as they become more accessible and affordable,are increasingly being used in rehabilitation to allow patients to engage in repetitive practice of specific tasks. a number of published reviews and meta-analyses have examined the use of vr and video games for post-stroke rehabilitation, focusing on or including ue rehabilitation. the authors agree that there is limited but promising findings that vr and video-games, when combined with traditional rehabilitation, have a positive impact on recovery post-stroke.

the goal of the study is to assess the feasibility, safety, and acceptability of the jintronix system, as well as provide preliminary evidence regarding the clinical efficacy for post-stroke rehabilitation.this is a pilot parallel randomised single-blinded controlled trial, with patients who have had a stroke randomly allocated to one of two groups: (1) usual rehabilitation services and additional training with jintronix system (treatment group) or (2) usual rehabilitation services only (control group).

Eligibility criteria:
inclusion criteria: * having had an ischemic or hemorrhagic stroke for the first time; * having residual mild to moderate ue impairment (score 3-6 on the chedoke-mcmaster arm component, as long as exergames can be played); * being in subacute stage (within 6 months post-stroke); * receiving usual out-patient rehabilitation services at one of the two selected rehabilitation sites, located in the greater montreal area in canada. exclusion criteria: * being medically unstable; * having severe cognitive or communication deficits; * having visual impairments limiting use of the exergame; * having any medical contraindication for shoulder movements; * having severe balance deficits limiting sitting safely independently; * having previous upper limb impairment limiting potential recovery; * having any other impairment that limited use of the exergame.

Keywords: virtual reality exergame stroke rehabilitation
metabolic outcomes in patients receiving tyrosine kinase inhibitor (tki) therapy with dasatinib or nilotinib

Conditions: Chronic Myeloid Leukemia (CML)

Summary: the purpose of this study was to determine how often and how likely patients are to develop type 2 diabetes or high cholesterol/lipids when receiving dasatinib or nilotinib as therapy for chronic myelogenous leukemia (cml).


Eligibility criteria:
inclusion criteria: * 18 years of age or older * at least 1 prescription for nilotinib or dasatinib between 7/1/2006-12/31/2014 * continuously enrolled in the same health plan throughout the study period * at least 2 diagnosis codes for cml at least 30 days apart as documented in medical insurance claims exclusion criteria: * patients who had a documented diagnosis of diabetes in their medical claims or received a medication for diabetes before receiving dasatinib or nilotinib * patients who had a documented diagnosis of high cholesterol/lipids in their medical claims or received a medication for high cholesterol/lipids before receiving dasatinib or nilotinib
examination of trends in non-small cell lung cancer patients' medical study experiences

Conditions: Non-Small Cell Lung Cancer

Summary: medical study participation percentages haven't always been fully representative of a given demographic. the goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. participating in an observational clinical trial may help patients with non-small cell lung cancer since it advances medical knowledge and may improve treatment choices in the future.


Eligibility criteria:
inclusion criteria: * participant has a diagnosis of non-small cell lung cancer * patient has self-identified as planning to enroll in a clinical trial for non-small cell lung cancer * patient is at least 18 years of age exclusion criteria: * inability to perform regular electronic reporting * any mental or medical condition that prevents the patient from giving informed consent or participating in the trial * pregnant or lactating woman

Keywords: non-small cell lung cancer